Here are the 424B prospectus supplements from Scribe Therapeutics Inc. (SCTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCTX filings page.
Scribe Therapeutics Inc. is conducting an initial public offering of 8,580,000 shares of common stock at $15.00 per share, for a gross offering size of $128.7 million. Net proceeds to the company are expected to be $13.95 per share, or $119.7 million before expenses, with underwriters holding a 30‑day option to purchase up to 1,287,000 additional shares. A concurrent private placement will sell 500,000 shares to Sanofi at the IPO price; this placement is contingent on but not a condition to the IPO.
The company is a clinical-stage biotechnology firm developing in vivo CRISPR-based genetic medicines, led by STX‑1150 for durable LDL‑C lowering in a first‑in‑human trial in up to 64 adults, with initial data expected in the first half of 2027, and preclinical programs STX‑1200 and STX‑1400 targeting Lp(a) and APOC3. Operations have been funded primarily through equity, collaborations, and grants; Scribe reported $51.2 million in 2025 collaboration revenue and a $21.8 million net loss, with an accumulated deficit of $175.1 million and $49.7 million in cash, cash equivalents, and short‑term investments as of March 31 2026.
Audited financial statements include a going‑concern warning, as existing cash would not support operations for twelve months absent new capital. Management believes current cash plus IPO and private‑placement proceeds will fund operations into the first half of 2029, but the business remains highly dependent on successful development of its pipeline and future financings. Scribe is an emerging growth company and smaller reporting company and will provide reduced disclosures under applicable regulations.